1. **Remit**

The Genetics NQAAP is responsible for monitoring participant performance in UK External Quality Assessment schemes in Clinical Laboratory Genetics (Biochemical Genetics, Cytogenetics and Molecular Genetics) plus other relevant molecular pathology services as designated by the Joint Working Group. This remit is based on the Joint Working Group for Quality Assessment in Pathology terms of reference and conditions of participation for EQA Schemes and should be read in conjunction with those documents.

The NQAAP is responsible for promoting, coordinating and protecting high professional standards in EQA and encouraging the development of clinically relevant and appropriate EQA schemes.

The panel fulfils its remit by:

(i) Reviewing and approving all UK EQA Schemes relating to the practice of clinical laboratory genetics plus relevant molecular pathology services. This will include agreed criteria for performance standards and the management of persistent substandard performance in these schemes

(ii) Receiving information on persistently poorly performing laboratories from EQA Scheme organisers (within two weeks of a laboratory being identified as a persistent poor performer) and managing the referrals within an appropriate timescale.

(iii) Agreeing with scheme organising’s mechanisms for resolution of persistent poor performance. Generally the scheme organiser will make contact with the laboratory in accordance with the scheme standard operating procedure and inform the Chair of the panel with the proposed remedial action to be taken including the timescale. If this does not lead to a resolution the Chair of the panel will offer advice to the laboratory and, if appropriate, will arrange a visit to the laboratory by a panel member or an agreed expert. If persistent poor performance remains unresolved the panel Chair will submit a report to the Chair of the Joint Working Group for Quality Assessment in Pathology

(iv) Receiving and resolving complaints from scheme participants where these have not been resolved by the scheme organisers or steering committees

(v) Producing an Annual report of its activities for the Royal College of Pathologists and the Joint Working Group on Quality Assessment in Pathology.
2. **Accountability**
The panel is accountable to the Joint Working Group for Quality Assessment in Pathology, which in turn is accountable to The Royal College of Pathologists, Professional Performance Panel.

3. **Membership**
The membership comprises:

- a chair appointed by the Royal College of Pathologists
- four nominees of the Association for Clinical Genetics Science (ACGS)
- a nominee of the British Society for Haematology (BSH)
- a nominee of the Association for Clinical Biochemistry and Laboratory Medicine (ACB)
- a nominee of the Associated Genetic Technologists Committee (AGTC)
- a nominee of the Institute of Biomedical Science (IBMS).

In addition specialist advisers may be co-opted to ensure appropriate expertise within the Panel. These specialist advisers currently include scheme organisers or delegates from the following EQA schemes:

- UK NEQAS for Clinical Cytogenetics
- UK NEQAS for Molecular Genetics
- UK NEQAS for Leucocyte Immunophenotyping (Molecular Haemato-oncology SAG).
- European Molecular Genetics Quality Network (EMQN)
- European Research Network for evaluation and improvement of screening, Diagnosis and treatment of Inherited Disorders of Metabolism (ERNDIM)

Other specialist observers attend when appropriate including representation from:

- Newborn Screening Committee.
- UKMRD and EuroMRD Networks

One of the nominated members of the panel will be designated as Deputy Chair.

All members normally serve a three-year term of office and are eligible for one further term (with the exception of the Chair and Deputy Chair who may serve a maximum of three terms on the panel).

4. **Operation**
The Panel meets twice yearly, usually in March and October. Minutes of the meetings are produced and distributed to Panel members. Business is also conducted by email where appropriate.

Meetings of the panel will be quorate when more than 30% of the nominated members are present.

The Panel produces an annual report that is submitted to the Royal College of Pathologists, Joint Working Group for Quality Assessment and professional organisations represented on the panel.

It is expected that a member of the Panel should be present at EQA Scheme Provider Steering Group meetings, at least annually.

Expenses of the Panel are claimed from the Royal College of Pathologists (from a fund created by a levy on EQA providers).